Huizenga Theodore Alan 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Sep 8, 2025
Insider Transaction Report
Form 4
Huizenga Theodore Alan
SVP, Chief Accounting Officer
Transactions
- Sale
Common Stock
2025-09-05$31.39/sh−84$2,637→ 50,306 total
Footnotes (3)
- [F1]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F2]Includes 266 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on April 30, 2025.
- [F3]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.